EA202190818A1 - COMBINED THERAPY FOR CANCER - Google Patents

COMBINED THERAPY FOR CANCER

Info

Publication number
EA202190818A1
EA202190818A1 EA202190818A EA202190818A EA202190818A1 EA 202190818 A1 EA202190818 A1 EA 202190818A1 EA 202190818 A EA202190818 A EA 202190818A EA 202190818 A EA202190818 A EA 202190818A EA 202190818 A1 EA202190818 A1 EA 202190818A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
combined therapy
antagonist
antigen
antibody
Prior art date
Application number
EA202190818A
Other languages
Russian (ru)
Inventor
Сандип П. Инамдар
Хелен Л. Коллинс
Хун Сян
Сян ЧЖАН
Нейсса Марина
Original Assignee
Файв Прайм Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Файв Прайм Терапьютикс, Инк. filed Critical Файв Прайм Терапьютикс, Инк.
Priority claimed from PCT/US2019/056210 external-priority patent/WO2020081497A1/en
Publication of EA202190818A1 publication Critical patent/EA202190818A1/en

Links

Abstract

В настоящем изобретении представлены способы введения антител и их антигенсвязывающих фрагментов, которые специфически связываются с B7-H4 человека, субъекту, нуждающемуся в этом, например пациенту с онкологическим заболеванием, в комбинации с антагонистом PD-1/PD-L1, таким как антитело к PD-1.The present invention provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example a patient with cancer, in combination with a PD-1 / PD-L1 antagonist such as an anti-PD antibody -one.

EA202190818A 2019-05-30 2019-10-15 COMBINED THERAPY FOR CANCER EA202190818A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854494P 2019-05-30 2019-05-30
PCT/US2019/056210 WO2020081497A1 (en) 2018-10-15 2019-10-15 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
EA202190818A1 true EA202190818A1 (en) 2021-10-27

Family

ID=78572599

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190818A EA202190818A1 (en) 2019-05-30 2019-10-15 COMBINED THERAPY FOR CANCER

Country Status (1)

Country Link
EA (1) EA202190818A1 (en)

Similar Documents

Publication Publication Date Title
EA201891178A1 (en) Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use
MX2019004692A (en) Anti-human 4-1 bb antibodies and use thereof.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA202092933A1 (en) ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY
EA201891983A1 (en) COMBINED THERAPY WITH ANTIBODIES TO CD73
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201790339A1 (en) COMBINED DRUGS WITH ANTIBODIES TO CD40
MX2021004808A (en) Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof.
EA202091747A1 (en) ANTIBODY B7-H4 COMPOSITIONS
MX2021004226A (en) Combination therapy for cancer.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2020009037A (en) B7-h4 antibodies and methods of use thereof.
MX2021008958A (en) Anti-il2 receptor gamma antigen-binding proteins.
MX2020008730A (en) B7-h4 antibody dosing regimens.
WO2019028182A3 (en) Cancer treatment using antibodies that bind human cd134 (ox40) receptor
MX2020008122A (en) Anti-pd-1 antibodies.
MX2019013753A (en) Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
EA201992316A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC OF PROSTATE CANCER
MX2022001841A (en) Antibodies against ilt2 and use thereof.
MX2020009902A (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor.
MX2021003673A (en) Anti-human vsig4 antibodies and uses thereof.
MX2023001776A (en) Antibodies against ilt2 and use thereof.